Columbia Labs Advantage-S Additional HIV Prevention Trials Unlikely
This article was originally published in The Tan Sheet
"It will be very difficult to conduct another study" on Advantage-S (nonoxynol-9) and HIV prevention after a Joint U.N. Program on HIV/AIDS trial produced negative results, Columbia Labs Chairman and CEO William Bologna asserted during a June 12 conference call.
You may also be interested in...
FDA is seeking guidance from the Antiviral Drugs Advisory Committee as to whether clinical trials on topical microbicides should include a "no treatment" (condom only) arm
The Centers for Disease Control & Prevention is advising against future purchases of condoms lubricated with nonoxynol-9 (N-9) spermicide
A recent study on nonoxynol-9 gel confirms its inadequacy as a microbicide and lends further proof of its suspected irritant effects, according to an editorial in the March 6 Journal of the American Medical Association